A=Advisory panel B=Speakers’ bureau C=Consultant F=Fellowship support G=Grant support H=Honoraria
O=Other financial benefit R=Royalties S=Stock owner W=Expert witness

Disc 1

1   The Changing World of Oral Anticoagulation (3:30)

Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

2   ISAR-REACT 3A: Reduced Dose Unfractionated Heparin in Biomarker Negative Patients Undergoing PCI (6:34)

Stefanie Schulz, MD, Munich, Germany

This author has nothing to disclose.

Interviewer: Albert L. Waldo, MD, FACC

This author has nothing to disclose.

3   LESSON I: Newer Generation Stents Show Benefit over Earlier Stents, but Why Is Unclear (7:10)

Petr Widimsky, MD, DSc, Prague, Czech Republic

This author has nothing to disclose.

Interviewer: Erik Magnus Ohman, MD, FACC

The Medicines Company (C,H); Merck & Co (C,H); Roche (C,H); sanofi-aventis (C,H); Gilead Sciences (C,H); Eli Lilly & Co (G); Daiichi-Sankyo (G)

4   Innovative Strategies in Chile Significantly Improve Outcomes for Patients with MI (7:30)

Edgardo Escobar, MD, Santiago, Chile

This author has nothing to disclose.

Interviewer: C. Richard Conti, MD, MACC

This author has nothing to disclose.

5   Standard vs High-dose Clopidogrel According to Platelet Function Testing After PCI: Results of the GRAVITAS Trial (13:26)

Matthew J. Price, MD, FACC, La Jolla, CA

Accumetrics, Inc (C,H); Daiichi-Sankyo (C,H); AstraZeneca (C,H); BristoMyers Squibb/sanofi-aventis (C,G,H); The Medicines Company (C,H); Daiichi-Sankyo/Eli Lilly & Co (S)

Interviewers: Erik Magnus Ohman, MD, FACC

The Medicines Company (C,H); Merck & Co (C,H); Roche (C,H); sanofi-aventis (C,H); Gilead Sciences (C,H); Eli Lilly & Co (G); Daiichi-Sankyo (G)

Deepak Bhatt, MD, FACC

AstraZeneca (G); Bristol-Myers Squibb (G); Eisai (G); sanofi-aventis (G); The Medicines Company (G)

6   Limus-Eluting Drugs Just as Safe as Bare-Metal Stents in Large Vessels (9:05)

Christoph A. Kaiser, MD, Basel, Switzerland

This author has nothing to disclose.

Interviewer: S. Ben Freedman, MBBS, FACC

This author has nothing to disclose.

7   New Biomarkers in Acute Cardiac Care  —   Markers of Necrosis (7:51)

W. Frank Peacock, IV, MD, Cleveland, OH

Beckman Coulter (C,H); Alere (B,C,G,H); Abbott (B,C,G,H); Nanosphere (G); Roche (G); Brahms (G)

Interviewer: Benjamin M. Scirica, MD, MPH, FACC

Roche (G); Bayer (G)

8   RIKS HIA: Preventive Therapy in Sweden Cuts Mortality in Half When Acute MI Strikes (5:18)

Tomas Jernberg, MD, Stockholm, Sweden

This author has nothing to disclose.

Interviewer: Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

Disc 2

1   What’s New in Asymptomatic Mitral Regurgitation: Is Delaying Surgery Failing Our Patients? (9:21)

Maurice Enriquez-Sarano, MD, FACC, Rochester, MN
This author has nothing to disclose.

Interviewer: Robert O. Bonow, MD, MACC

This author has nothing to disclose.

2   Fluid Overload in Acute Heart Failure: The Cause or the Result? (7:00)

Gad Cotter, MD, Durham, NC
This author has nothing to disclose.

Interviewer: Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

3   ASCEND-HF: Nesiritide is Safe but Largely Ineffective for Severe Heart Failure (6:45)

Randall C. Starling, MD, MPH, FACC, Cleveland, OH

Johnson & Johnson (G); Novartis (G); Medtronic (G)

Interviewer: Christopher M. Kramer, MD, FACC

This author has nothing to disclose.

4   Controversies in Hypertension  —  Are Diuretics Still First-line Therapy? (8:07)

Suzanne Oparil, MD, FACC, Birmingham, AL

This author has nothing to disclose.

Interviewer: C. Richard Conti, MD, MACC

This author has nothing to disclose.

5   Sudden Cardiac Death and Hypertrophic Cardiomyopathy: A Critical Analysis (7:01)

William H. Spencer, III, MD, FACC, Charleston, SC

This author has nothing to disclose.

Interviewer: Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

6   Status of Mitral Valve Therapy (5:01)

Blase A. Carabello, MD, FACC, Houston, TX

This author has nothing to disclose.

Interviewer: Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

7   JACC: Optimal Left Ventricular Endocardial Pacing Sites for Cardiac Resynchronization Therapy in Patients with Ischemic Cardiomyopathy (3:54)

David D. Spragg, MD, Columbia, MD

This author has nothing to disclose.

Interviewer: Anthony N. DeMaria, MD, MACC

Cardionet (S); Acusphere (G); Cardiovascular Biotherapeutics (G); GE Medical Systems (G); Borhinger Ingleheim (C,H); Angioblast Systems, Inc (G); sanofi-aventis (C,H); CV Therapeutics (G); Lantheus (G); Philips Medical Systems (G)
http://content.onlinejacc.org/cgi/content/abstract/56/10/774

Disc 3

1   Heart Failure Hospital to Home Program (3:47)

Harlan M. Krumholz, MD, SM, FACC, New Haven, CT

This author has nothing to disclose.

Interviewer: Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

2   Coarctation of the Aorta:Neither a Simple nor Isolated Congenital Anomaly (5:39)

Carole A. Warnes, MD, FACC, Rochester, MN

This author has nothing to disclose.

Interviewer: Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

3   PCI Therapy in the Elderly (6:11)

Ralph G. Brindis, MD, MPH, FACC, San Francisco, CA

This author has nothing to disclose.

Interviewer: Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

4   Is Low High-Density Lipoprotein Still an Important Issue? (7:58)

Julian P. Halcox, MA, London United Kingdom

MSD (C,H,S); AstraZeneca (C,H,S); Pfizer (C,H,S)

Interviewer: Albert L. Waldo, MD, FACC
This author has nothing to disclose.

5   REACH Registry Reveals International Pandemic of Cardiovascular Disease (13:34)

Deepak L. Bhatt, MD, MPH, FACC, Newton, MA

AstraZeneca (G); Bristol-Myers Squibb (G); Eisai (G); sanofi-aventis (G); The Medicines Company (G)

Interviewer: Alfred A. Bove, MD, PhD, MACC, Philadelphia, PA

Agency for Healthcare Research and Quality (G); Insight Telehealth Systems Inc (C,H); Elsevier (R)

6   ROCKET-AF: Rivaroxiban Comparable to Warfarin for Preventing AF-Related Stroke with No Need for Monitoring (8:01)

Kenneth W. Mahaffey, MD, FACC, Durham, NC

Adolor Corporation (C,H); Alexion (C,H); Amgen, Inc (C,G,H); Argolyn (C,H); AstraZeneca (C,G,H); Bayer Healthcare (C,G,H); Boehringer Ingelheim (C,G,H); Brigham and Women’s Hospital (C,H); Bristol-Myers Squibb (C,G,H); Daiichi-Sankyo (C,H); Duke University School of Medicine (C,H); Eli Lilly & Co (C,G,H); Elsevier (C,H); Forest Labs (C,H); Genentech (C,G,H); GlaxoSmithKline (C,G,H); Guidant Corporation (C,H); Johnson & Johnson (C,G,H); Merck & Co (C,G,H); Novartis (C,G,H); Pfizer (C,H); Procter & Gamble (C,H); sanofi-aventis (C,G,H); Schering-Plough (C,G,H); Scios, Inc (C,H); WebMD (C,H); Abbott Vascular (G); Amylin, Inc (G); CardioKinetix, Inc (G); Cierra (G); Cordi (G); Edwards Lifesciences (G); Guidant Corp (G); Innocoll Pharmaceuticals (G); KCI Medical (G); Luitpold Pharmaceutical (G); Medtronic, Inc (G); Momenta Pharmaceutical (G); Portola Pharmaceutical (G); Pozen (G); Regado (G); The Medicines Company (G)

Interviewer: Robert A. Vogel, MD, FACC

This author has nothing to disclose.

7   Has Carotid Artery Intervention CRESTed? (10:07)

Christopher J. White, MD, FACC, New Orleans, LA

Boston Scientific (C,H)

Interviewer: Peter A. McCullough, MD, MPH, FACC

This author has nothing to disclose.

8   Genetics of Sudden Death in Coronary Artery Disease (10:11)

Sumeet S. Chugh, MD, FACC, Los Angeles, CA

This author has nothing to disclose.

Interviewer: James H. Chesebro, MD, FACC

This author has nothing to disclose.